View Future GrowthVerici Dx 과거 순이익 실적과거 기준 점검 0/6Verici Dx은 연평균 10.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 84.9%의 비율로 증가했습니다.핵심 정보10.28%순이익 성장률26.87%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률84.86%자기자본이익률-306.85%순이익률-398.12%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023모든 업데이트 보기Recent updates공시 • 20hVerici Dx Receives New York State Approval for Tutivia Kidney Transplant Rejection TestVerici Dx plc received clinical laboratory accreditation from the New York State Department of Health Clinical Laboratory Evaluation Program. The Company also received New York state approval of Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. By detecting rejection-associated biological mechanisms, the Tutivia test provides clinicians with a proactive indicator of rejection risk, enabling more precise patient management and risk stratification, better-timed interventions, and the potential to reduce avoidable biopsies and graft loss. With this New York state certification, Verici Dx is now authorized to provide laboratory testing services in all 50 U.S. states and the District of Columbia, creating nationwide availability of the Tutivia test. Tutivia combines transcriptomics with proprietary machine learning algorithm to deliver predictive intelligence for acute kidney transplant rejection. The test provides clinicians with deeper insight to support more precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemia–reperfusion injury, which can confound conventional blood tests including serum creatinine and cell-free DNA. The science underlying Tutivia was pioneered at The Mount Sinai Hospital in New York. Its development is grounded in decades of clinical expertise and scientific rigor, and New York State approval represents a full-circle milestone, bringing a locally developed innovation back to the state’s transplant community with nationwide reach. The Tutivia test was validated in a clinical study that included a broad and diverse transplant patient population.공시 • Jun 24Verici Dx plc Receives New York State Clinical Laboratory CertificationVerici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, announced that it has received clinical laboratory certification from the New York State Department of Health Clinical Laboratory Evaluation Program. Having achieved New York state certification, the nation's most rigorous laboratory evaluation program, Verici Dx has now completed its full authorisation to provide laboratory testing services in all 50 US states and the District of Columbia, creating nationwide availability of the Tutivia test. The Company also received state approval for Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant.공시 • Jun 12Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 53,345,832 Price\Range: AUD 0.0035공시 • Jun 10Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 57,142,857 Price\Range: AUD 0.0035공시 • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.공시 • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.공시 • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.공시 • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005공시 • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005공시 • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom공시 • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024공시 • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024공시 • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing공시 • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.공시 • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.공시 • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.공시 • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.공시 • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023매출 및 비용 세부 내역Verici Dx가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VRCD.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 252-89031 Mar 253-79031 Dec 243-69030 Sep 244-58030 Jun 244-58031 Mar 243-78031 Dec 231-99030 Sep 231-109030 Jun 230-1110031 Mar 230-1110031 Dec 220-1110030 Sep 220-1110030 Jun 220-1110031 Mar 220-108031 Dec 210-870양질의 수익: VRCD.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: VRCD.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VRCD.F는 수익성이 없지만 지난 5년 동안 연평균 10.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VRCD.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VRCD.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VRCD.F는 현재 수익성이 없으므로 자본 수익률이 음수(-306.85%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 14:28종가2026/03/12 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Verici Dx plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024
공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024
공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023
공시 • 20hVerici Dx Receives New York State Approval for Tutivia Kidney Transplant Rejection TestVerici Dx plc received clinical laboratory accreditation from the New York State Department of Health Clinical Laboratory Evaluation Program. The Company also received New York state approval of Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. By detecting rejection-associated biological mechanisms, the Tutivia test provides clinicians with a proactive indicator of rejection risk, enabling more precise patient management and risk stratification, better-timed interventions, and the potential to reduce avoidable biopsies and graft loss. With this New York state certification, Verici Dx is now authorized to provide laboratory testing services in all 50 U.S. states and the District of Columbia, creating nationwide availability of the Tutivia test. Tutivia combines transcriptomics with proprietary machine learning algorithm to deliver predictive intelligence for acute kidney transplant rejection. The test provides clinicians with deeper insight to support more precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemia–reperfusion injury, which can confound conventional blood tests including serum creatinine and cell-free DNA. The science underlying Tutivia was pioneered at The Mount Sinai Hospital in New York. Its development is grounded in decades of clinical expertise and scientific rigor, and New York State approval represents a full-circle milestone, bringing a locally developed innovation back to the state’s transplant community with nationwide reach. The Tutivia test was validated in a clinical study that included a broad and diverse transplant patient population.
공시 • Jun 24Verici Dx plc Receives New York State Clinical Laboratory CertificationVerici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, announced that it has received clinical laboratory certification from the New York State Department of Health Clinical Laboratory Evaluation Program. Having achieved New York state certification, the nation's most rigorous laboratory evaluation program, Verici Dx has now completed its full authorisation to provide laboratory testing services in all 50 US states and the District of Columbia, creating nationwide availability of the Tutivia test. The Company also received state approval for Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant.
공시 • Jun 12Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 53,345,832 Price\Range: AUD 0.0035
공시 • Jun 10Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 57,142,857 Price\Range: AUD 0.0035
공시 • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.
공시 • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.
공시 • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.
공시 • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005
공시 • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005
공시 • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
공시 • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.
공시 • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024
공시 • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
공시 • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024
공시 • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
공시 • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.
공시 • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.
공시 • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.
공시 • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.
공시 • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom
공시 • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023